Predict Parkinson progression using neuroimaging

Trial ID
NCT07024875
Official Title
Precision Neuroimaging of Parkinson's Disease
Goal
Predict Parkinson progression using neuroimaging
Status
RECRUITING
Sponsor
Washington University School of Medicine
Study Type
OBSERVATIONAL
Enrollment
120 participants
Conditions
Parkinsons Disease (PD)

Plain-Language Summary

The goal is to use high-precision MRI to identify brain markers that track Parkinson's progression and link specific brain changes to motor and cognitive symptoms, so diagnosis and care can be more personalized. The approach is non-invasive advanced neuroimaging, using structural and functional MRI to map brain anatomy and activity patterns; the scans do not change your medications or interact with levodopa, they just let researchers see how brain circuits relate to symptoms. They are enrolling adults 50 and older with a clinical diagnosis of Parkinson's who do not meet criteria for dementia, plus healthy volunteers with normal cognition and no first-degree relatives with PD, and they exclude people with other neurological or serious medical or psychiatric conditions, major head injury, or MRI contraindications like metal implants or claustrophobia.

Locations

  • East Imaging Building, St Louis, Missouri, United States

Frequently Asked Questions

What is this trial testing?
This trial is studying an experimental treatment. The goal is to use high-precision MRI to identify brain markers that track Parkinson's progression and link specific brain changes to motor and cognitive symptoms, so diagnosis and care can be more personalized. The approach is non-invasive advanced neuroimaging, using structural and functional MRI to map brain anatomy and activity patterns; the scans do not change your medications or interact with levodopa, they just let researchers see how brain circuits relate to symptoms. They are enrolling adults 50 and older with a clinical diagnosis of Parkinson's who do not meet criteria for dementia, plus healthy volunteers with normal cognition and no first-degree relatives with PD, and they exclude people with other neurological or serious medical or psychiatric conditions, major head injury, or MRI contraindications like metal implants or claustrophobia.
Who can participate?
Participants must be at least 40 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 5 years and 5 months.

View on ClinicalTrials.gov